Skip to main content

Nuplazid and Alcohol/Food Interactions

There is 1 alcohol/food/lifestyle interaction with Nuplazid (pimavanserin).

Moderate

Pimavanserin Obesity

Moderate Potential Hazard, Moderate plausibility

atypical antipsychotic agents - hyperglycemia/diabetes

Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents. Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents. It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.

References

  1. (2001) "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals
  2. (2001) "Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals
  3. (2001) "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company
  4. (2001) "Product Information. Seroquel (quetiapine)." Astra-Zeneca Pharmaceuticals
  5. (2001) "Product Information. Geodon (ziprasidone)." Pfizer U.S. Pharmaceuticals
  6. (2002) "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb
  7. (2007) "Product Information. Invega (paliperidone)." Janssen Pharmaceuticals
  8. (2009) "Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc
  9. (2009) "Product Information. Saphris (asenapine)." Schering-Plough Corporation
  10. (2010) "Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc
  11. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
  12. (2015) "Product Information. Vraylar (cariprazine)." Actavis Pharma, Inc.
  13. (2022) "Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc., SUPPL-9
View all 13 references

Nuplazid drug interactions

There are 364 drug interactions with Nuplazid (pimavanserin).

Nuplazid disease interactions

There are 9 disease interactions with Nuplazid (pimavanserin) which include:

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer